Cue Biopharma, Inc. Net Income Loss

• Cue Biopharma, Inc. showed an increase of +34.6% in Net Income Loss from 2024 to 2025.
• This data is from Cue Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), Cue Biopharma, Inc.'s Net Income Loss has declined by 14.5%.
• Historical annual values: Fiscal year 2025: -$26.60 million | Fiscal year 2024: -$40.67 million | Fiscal year 2023: -$50.73 million | Fiscal year 2022: -$53.01 million | Fiscal year 2021: -$44.16 million | Fiscal year 2020: -$44.78 million | Fiscal year 2019: -$36.70 million | Fiscal year 2018: -$38.98 million | Fiscal year 2017: -$23.23 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026